The Gastrointestinal Diseases Therapeutics Market is being driven by Increasing incidence of gastrointestinal diseases
The Gastrointestinal Diseases Therapeutics Market is expected to grow at a CAGR of 7.1% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 20683.2 million. In the realm of gastrointestinal diseases therapeutics, nutritional approaches hold substantial significance. Specialized diets and dietary supplements serve as essential tools for managing symptoms and enhancing the quality of life for patients dealing with various gastrointestinal conditions. Notable diseases, such as irritable bowel syndrome (IBS) and celiac disease, exhibit positive responses to dietary modifications. The guidance of healthcare providers and registered dietitians is indispensable for patients implementing these dietary adjustments. The low-FODMAP diet, which eliminates fermentable carbohydrates triggering IBS symptoms, is an illustrative example of a specialized dietary strategy. The market for low-FODMAP resources and certified food products caters to the needs of patients adhering to this diet. For individuals diagnosed with celiac disease or non-celiac gluten sensitivity, a strict gluten-free diet is imperative. The availability of comprehensive resources and certified gluten-free products is crucial in facilitating successful adherence to this dietary regimen.
Get more information on Gastrointestinal Diseases Therapeutics Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
215 |
|
Base year |
2024 |
|
Historic period |
2019-2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.1% |
|
Market growth 2025-2029 |
USD 20683.2 million |
|
Market structure |
fragmentation |
|
YoY growth 2024-2025(%) |
6.5 |
|
Key countries |
US, China, Canada, Germany, Japan, UK, India, France, Italy, and South Korea |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Gastrointestinal (GI) Diseases Therapeutics Market encompasses a range of treatments for disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), gastrointestinal cancers, autoimmune diseases like Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and specific GI conditions such as Crohn's disease and ulcerative colitis. Novel therapies and targeted drugs are increasingly being developed to address the chronic nature of these digestive diseases using GI drugs.
The gastrointestinal diseases therapeutics market encompasses pharmaceutical companies and researchers involved in the development and production of both generic and non-generic drugs, as well as veterinary drugs. According to Technavio's market analysis, the global pharmaceuticals market's growth is attributed to several factors, including the increasing aging population. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to be over 60 years old. This demographic shift will drive market expansion, as older populations are more prone to gastrointestinal conditions such as gastroesophageal reflux disease, inflammatory bowel disease, irritable bowel syndrome, and gastrointestinal cancers. The global healthcare market size is calculated based on the collective revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
